Microvascular coronary dysfunction and ischemic heart disease: Where are we in 2014?

Trends in Cardiovascular Medicine

Volumn 25, Issue 2, 2015, Pages 98-103

  Petersen, John W ^a   Pepine, Carl J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANGINA PECTORIS AGENT;

ANGINA PECTORIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; ENDOTHELIAL DYSFUNCTION; EPICARDIAL CORONARY DISEASE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE FUNCTION; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; MICROANGIOPATHY; MICROVASCULAR CORONARY DYSFUNCTION; MORPHOLOGY; PRIORITY JOURNAL; REVIEW; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; FEMALE; MALE; MICROVASCULATURE; MYOCARDIAL ISCHEMIA; PATHOLOGY;

CORONARY ARTERY DISEASE; CORONARY VESSELS; FEMALE; HUMANS; MALE; MICROVESSELS; MYOCARDIAL ISCHEMIA;

EID: 84923025249     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2014.09.013     Document Type: Review

References (40)

1. Likoff W., Segal B.L., Kasparian H. Paradox of normal selective coronary arteriograms in patients considered to have unmistakable coronary heart disease. N Engl J Med 1967, 276:1063-1066.
2. Kemp H.G. Left ventricular function in patients with the anginal syndrome and normal coronary arteriograms. Am J Cardiol 1973, 32:375-376.
3. Cannon R.O., Epstein S.E. "Microvascular angina" as a cause of chest pain with angiographically normal coronary arteries. Am J Cardiol 1988, 61:1338-1343.
4. Luke R.G. Hypertensive nephrosclerosis: pathogenesis and prevalence. Essential hypertension is an important cause of end-stage renal disease. Nephrol Dial Transplant 1999, 14:2271-2278.
5. Vermeltfoort I.A., Raijmakers P.G., Riphagen I.I., Odekerken D.A., Kuijper A.F., Zwijnenburg A., et al. Definitions and incidence of cardiac syndrome X: review and analysis of clinical data. Clin Res Cardiol 2010, 99:475-481.
6. Ong P., Athanasiadis A., Borgulya G., Mahrholdt H., Kaski J.C., Sechtem U. High prevalence of a pathological response to acetylcholine testing in patients with stable angina pectoris and unobstructed coronary arteries the ACOVA study (Abnormal COronary VAsomotion in patients with stable angina and unobstructed coronary arteries). J Am Coll Cardiol 2012, 59:655-662.
7. Jespersen L., Hvelplund A., Abildstrøm S.Z., Pedersen F., Galatius S., Madsen J.K., et al. Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events. Eur Heart J 2012, 33:734-744.
8. Fihn S.D., Blankenship J.C., Alexander K.P., Bittl J.A., Byrne J.G., Fletcher B.J., et al. ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2014, [Epub ahead of print]. 10.1161/CIR.0000000000000095.
9. Shaw L.J., Merz C.N., Pepine C.J., Reis S.E., Bittner V., Kip K.E., et al. The economic burden of angina in women with suspected ischemic heart disease: results from the National Institutes of Health-National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation. Circulation 2006, 114:894-904.
10. Reis S.E., Holubkov R., Conrad Smith A.J., Kelsey S.F., Sharaf B.L., Reichek N., et al. WISE investigators. Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: results from the NHLBI WISE study. Am Heart J 2001, 141:735-741.
11. Pepine C.J., Anderson R.D., Sharaf B.L., Reis S.E., Smith K.M., Handberg E.M., et al. Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women's Ischemia Syndrome Evaluation) study. J Am Coll Cardiol 2010, 55:2825-2832.
12. von Mering G.O., Arant C.B., Wessel T.R., McGorray S.P., Bairey Merz C.N., Sharaf B.L., et al. National Heart, Lung, and Blood Institute. Abnormal coronary vasomotion as a prognostic indicator of cardiovascular events in women: results from the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 2004, 109:722-725.
13. Camici P.G., Crea F. Coronary microvascular dysfunction. N Engl J Med 2007, 356:830-840.
14. Murthy V.L., Naya M., Taqueti V.R., Foster C.R., Gaber M., Hainer J., et al. Effects of sex on coronary microvascular dysfunction and cardiac outcomes. Circulation 2014, 129:2518-2527.
15. Merz C.N., Kelsey S.F., Pepine C.J., Reichek N., Reis S.E., Rogers W.J., et al. The Women's Ischemia Syndrome Evaluation (WISE) study: protocol design, methodology and feasibility report. J Am Coll Cardiol 1999, 33:1453-1461.
16. Petersen J.W., Johnson B.D., Kip K.E., Anderson R.D., Handberg E.M., Sharaf B., et al. TIMI frame count and adverse events in women with no obstructive coronary disease: a pilot study from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE). PLoS One 2014, 9:e96630.
17. Reis S.E., Holubkov R., Lee J.S., Sharaf B., Reichek N., Rogers W.J., et al. Coronary flow velocity response to adenosine characterizes coronary microvascular function in women with chest pain and no obstructive coronary disease. Results from the pilot phase of the Women's Ischemia Syndrome Evaluation (WISE) study. J Am Coll Cardiol 1999, 33:1469-1475.
18. van de Hoef T.P., van Lavieren M.A., Damman P., Delewi R., Piek M.A., Chamuleau S.A., et al. Physiological basis and long-term clinical outcome of discordance between fractional flow reserve and coronary flow velocity reserve in coronary stenoses of intermediate severity. Circ Cardiovasc Interv 2014, 7:301-311.
19. Caiati C., Montaldo C., Zedda N., Montisci R., Ruscazio M., Lai G., et al. Validation of a new noninvasive method (contrast-enhanced transthoracic second harmonic echo Doppler) for the evaluation of coronary flow reserve: comparison with intracoronary Doppler flow wire. J Am Coll Cardiol 1999, 34:1193-1200.
20. Dimitrow P.P. Transthoracic Doppler echocardiography-noninvasive diagnostic window for coronary flow reserve assessment. Cardiovasc Ultrasound 2003, 1:4.
21. Panting J.R., Gatehouse P.D., Yang G.Z., Grothues F., Firmin D.N., Collins P., et al. Abnormal subendocardial perfusion in cardiac syndrome X detected by cardiovascular magnetic resonance imaging. N Engl J Med 2002, 346:1948-1953.
22. Buchthal S.D., den Hollander J.A., Merz C.N., Rogers W.J., Pepine C.J., Reichek N., et al. Abnormal myocardial phosphorus-31 nuclear magnetic resonance spectroscopy in women with chest pain but normal coronary angiograms. N Engl J Med 2000, 342:829-835.
23. Nichols W.W., Denardo S.J., Johnson B.D., Sharaf B.L., Bairey Merz C.N., Pepine C.J. Increased wave reflection and ejection duration in women with chest pain and nonobstructive coronary artery disease: ancillary study from the Women's Ischemia Syndrome Evaluation. J Hypertens 2013, 31:1447-1454. [discussion 1454-5].
24. Maseri A., Mimmo R., Chierchia S., Marchesi C., Pesola A., L'Abbate A. Coronary artery spasm as a cause of acute myocardial ischemia in man. Chest 1975, 68:625-633.
25. Tschöpe C., Bock C.T., Kasner M., Noutsias M., Westermann D., Schwimmbeck P.L., et al. High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction. Circulation 2005, 111:879-886.
26. Paulus W.J., Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013, 62:263-271.
27. Galiuto L., De Caterina A.R., Porfidia A., Paraggio L., Barchetta S., Locorotondo G., et al. Reversible coronary microvascular dysfunction: a common pathogenetic mechanism in apical ballooning or Tako-Tsubo Syndrome. Eur Heart J 2010, 31:1319-1327.
28. Kaski J.C., Rosano G.M., Collins P., Nihoyannopoulos P., Maseri A., Poole-Wilson P.A. Cardiac syndrome X: clinical characteristics and left ventricular function. Long-term follow-up study. J Am Coll Cardiol 1995, 25:807-814.
29. Lanza G.A., Colonna G., Pasceri V., Maseri A. Atenolol versus amlodipine versus isosorbide-5-mononitrate on anginal symptoms in syndrome X. Am J Cardiol 1999, 84:854-856. [A858].
30. Skalidis E.I., Hamilos M.I., Chlouverakis G., Zacharis E.A., Vardas P.E. Ivabradine improves coronary flow reserve in patients with stable coronary artery disease. Atherosclerosis 2011, 215:160-165.
31. Villano A., Di Franco A., Nerla R., Sestito A., Tarzia P., Lamendola P., et al. Effects of ivabradine and ranolazine in patients with microvascular angina pectoris. Am J Cardiol 2013, 112:8-13.
32. Chaitman B.R. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation 2006, 113:2462-2472.
33. Mehta P.K., Goykhman P., Thomson L.E., Shufelt C., Wei J., Yang Y., et al. Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease. JACC Cardiovasc Imaging 2011, 4:514-522.
34. Shahin Y., Khan J.A., Samuel N., Chetter I. Angiotensin converting enzyme inhibitors effect on endothelial dysfunction: a meta-analysis of randomised controlled trials. Atherosclerosis 2011, 216:7-16.
35. Kaski J.C., Rosano G., Gavrielides S., Chen L. Effects of angiotensin-converting enzyme inhibition on exercise-induced angina and ST segment depression in patients with microvascular angina. J Am Coll Cardiol 1994, 23:652-657.
36. Pauly D.F., Johnson B.D., Anderson R.D., Handberg E.M., Smith K.M., Cooper-DeHoff R.M., et al. In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function: a double-blind randomized study from the National Heart, Lung and Blood Institute Women's Ischemia Syndrome Evaluation (WISE). Am Heart J 2011, 162:678-684.
37. Tiefenbacher C.P., Friedrich S., Bleeke T., Vahl C., Chen X., Niroomand F. ACE inhibitors and statins acutely improve endothelial dysfunction of human coronary arterioles. Am J Physiol Heart Circ Physiol 2004, 286:H1425-H1432.
38. Khuddus M.A., Pepine C.J., Handberg E.M., Bairey Merz C.N., Sopko G., Bavry A.A., et al. An intravascular ultrasound analysis in women experiencing chest pain in the absence of obstructive coronary artery disease: a substudy from the National Heart, Lung and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). J Interv Cardiol 2010, 23:511-519.
39. Stone G.W., Maehara A., Lansky A.J., de Bruyne B., Cristea E., Mintz G.S., et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med 2011, 364:226-235.
40. Reynolds H.R., Srichai M.B., Iqbal S.N., Slater J.N., Mancini G.B., Feit F., et al. Mechanisms of myocardial infarction in women without angiographically obstructive coronary artery disease. Circulation 2011, 124:1414-1425.